VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3%
Fri, 23 Nov

VENUS REMEDIES has announced its results for the quarter ended September 2018. Here is a detailed performance review of the same:

VENUS REMEDIES Quarterly Financials

No. of Mths
Qtr. Ending
3
Sep-17*
3
Jun-18*
3
Sep-18*
QoQ ChangeYoY Change
Net SalesRs m90565580923.5%-10.6%
Other incomeRs m1212640.0%862.6%
TurnoverRs m90665782125.0%-9.4%
ExpensesRs m73555464416.2%-12.4%
Gross profitRs m17110116562.8%-3.2%
DepreciationRs m7582830.7%9.7%
InterestRs m87779119.3%4.9%
Profit before taxRs m10-563-68.0%
TaxRs m00-50.0%0.0%
Profit after taxRs m10-568-16.3%
Gross profit margin%18.815.520.4
Effective tax rate%0.00.0-161.6
Net profit margin%1.1-8.51.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 10.6% on a year-on-year (YoY) basis. The expenses were down by 12.4% YoY during the same period.
  • The company's operating profit declined by 3.2% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.4% in 2QFY19 as against 18.8% in 2QFY18.
  • Depreciation charges increased by 9.7% and finance costs increased by 4.9% YoY, respectively.
  • Other income increased by 862.6% YoY during the quarter.
  • Net profit for the quarter declined by 16.3% YoY. Net profit margins during the quarter declined from 1.1% in 2QFY18 to 1.0% in 2QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 23.5% on a quarter-on-quarter (QoQ) basis. The expenses were up by 16.2% QoQ during the same period.
  • The company's operating profit increased by 62.8% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.4% in 2QFY19 as against 15.5% in 1QFY18.
  • Net profit for the quarter increased by 114.4% QoQ, while net profit margins increased from -8.5% in 1QFY18 to 1.0% in 2QFY19.

To see how VENUS REMEDIES has performed over the last eight quarters, please visit here.

VENUS REMEDIES Share Price Performance

Over the last one year, VENUS REMEDIES share price has moved up from Rs 102.6 to Rs 60.8, registering a Loss of Rs 41.8 or around 40.7%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,303.0 (down 0.6%). Over the last one year it has moved up from 13,976.3 to 14,303.0, a gain of 327 points (up 2.3%).

Overall, the S&P BSE SENSEX is up 4.2% over the year.

Current Valuations

At the current price of Rs 60.8, the price to book value (P/BV) ratio of VENUS REMEDIES stands at 0.2 times.

Equitymaster requests your view! Post a comment on "VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3%". Click here!

  

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 17, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS